BioMarin's $4.8 Billion Amicus Acquisition Signals New Wave of Rare Disease M&A
BioMarin Pharmaceutical announced plans to acquire Amicus Therapeutics for $4.8 billion, creating a rare disease powerhouse and signaling a new wave of biotech consolidation.